|Bid||4.9700 x 900|
|Ask||4.9800 x 1000|
|Day's Range||4.9500 - 5.2000|
|52 Week Range||4.9150 - 10.0900|
|Beta (5Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 15, 2022 - Feb 21, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.10|
Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.
Fennec (FENC) suffers a setback again with a CRL for its new drug application (NDA) for Pedmark. Shares are down in pre-market trading.
Bristol Myers (BMY) announces extension of FDA review of its cardiovascular drug mavacamten. The new target action date is Apr 28, 2022.